Treatments and Therapies | Alzheimer's Society

What is lecanemab?

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for use on the NHS. Here is what we know so far about this breakthrough Alzheimer's drug.

Research

Real stories

Reminiscence therapy helped my mum with dementia return to her roots

24 October 2023

Alzheimer's Society respond to FDA decision on Alzheimer's drug lecanemab

The Food and Drug Administration has today approved lecanemab, a new drug for Alzheimer's disease, for use across the US.

Alzheimer's Society comment on disappointing results for gantenerumab drug at clinical trial

Alzheimer's Society, study participant Eric Deeson and Sir Prof John Hardy comment on the disappointing clinical trial results for Alzheimer's drug gantenerumab.

Alzheimer's Society comment on today's 'breakthrough' Alzheimer's drug news

Dr Richard Oakley, Associate Director of Research at Alzheimer’s Society, comments on news surrounding breakthrough Alzheimer's drug lecanemab.

Progress with new Alzheimer’s drug lecanemab announced by manufacturers Eisai and Biogen

Yesterday (27 September 2022), Eisai Co. Ltd. and Biogen announced top-line results for a major trial on the drug lecanemab in slowing down the progress of Alzheimer’s disease. Alzheimer's Society comments on this Alzheimer’s progression drug hope.

Research

What is Aducanumab and what could this dementia drug mean for people with Alzheimer's disease?

22 December 2021

Alzheimer's Society responds to EMA rejection of aducanumab

The European Medicines Agency (EMA) has recommended that aducanumab, marketed as Aduhelm, is not approved for use across the EU. The drug was previously approved for use in the US by the Food and Drug Administration (FDA) on 7 June 2021.

Real stories

Art therapy helps my grandmother with her dementia and my autism

20 September 2021

Investigating how to clear toxic amyloid protein from the brain in Alzheimer’s disease

Research project: Understanding the molecular basis of Amyloid beta peptide interaction by neprilysin in Alzheimer’s disease.

Understanding the effects of the diabetes type 2 drug Metformin on models of Alzheimer’s disease

Research project: Metformin in Alzheimer’s disease

Positive drug trial results of a new treatment for dementia-related psychosis presented at Clinical Trials on Alzheimer’s Disease conference - Alzheimer's Society comment

Researchers presented results from a phase 3 trial of pimavanserin that showed a significant reduction in the risk of relapse into psychosis compared to the placebo.

Alzheimer's Society responds to Biogen, Aducanumab results at Clinical Trials on Alzheimer's Disease Conference (CTAD)

Biogen presented their results on Aducanumab, their newest drug for the treatment of Alzheimer's disease at the CTAD conference 2019 in San Diego, USA.